Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (251)
  2. Journal Article (103)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (4)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (380)
  2. Department of Medicine (380)
  3. Hematologic Malignancies Research (380)
  4. Hematologic Malignancies, Division of (380)
  5. Myeloma (380)
  6. Survivorship Research (225)

More Groups

People
  1. Hani Hassoun (202)
  2. Heather Landau (187)
  3. Sergio Giralt (185)
  4. David Chung (175)
  5. Neha Korde (174)
  6. Sham Mailankody (170)

More People

Years
  1. 2025 (11)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (41)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (12)

More Publications

Publishers
  1. American Society of Hematology (152)
  2. Elsevier Inc. (79)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (26)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (380)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Temporal genomic dynamics shape clinical trajectory in multiple myeloma
    Journal Article

    Maura, F.; Kaddoura, M.; Poos, A. M.; Baughn, L. B.; Ziccheddu, B.; Bärtsch, M. A.; Cirrincione, A.; Maclachlan, K.; Chojnacka, M.; Diamond, B.; more...
    Nature Genetics (2025)

    Fulltext@MSK | Save
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
    Correspondence

    Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma
    Journal Article

    Jagannath, S.; Martin, T. G.; Lin, Y.; Cohen, A. D.; Raje, N.; Htut, M.; Deol, A.; Agha, M.; Berdeja, J. G.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: A phase 1b open-label expansion study
    Journal Article

    Rodriguez, C.; Rodriguez, T.; Kentos, A.; Driessen, C.; Suanmi, K.; Lesokhin, A. M.; Yee, A. J.; Minella, A. C.; Maraboina, R.; Upreti, V. V.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
    Journal Article

    Einarsdottir, S.; Lobaugh, S.; Luan, D.; Gomez-Llobell, M.; Subramanian, P.; Devlin, S.; Chung, D.; Dahi, P. B.; Falchi, L.; Giralt, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Recycling is “bad to the bone” in patients with myeloma
    Editorial

    Miller, K. C.; Lesokhin, A. M.
    Blood (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save